Northern Trust’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-50,541
Closed -$7K 4320
2019
Q4
$7K Hold
50,541
﹤0.01% 4217
2019
Q3
$8K Hold
50,541
﹤0.01% 4200
2019
Q2
$8K Hold
50,541
﹤0.01% 4219
2019
Q1
$10K Hold
50,541
﹤0.01% 4171
2018
Q4
$35K Hold
50,541
﹤0.01% 4108
2018
Q3
$62K Hold
50,541
﹤0.01% 4109
2018
Q2
$56K Hold
50,541
﹤0.01% 4111
2018
Q1
$102K Sell
50,541
-4,833
-9% -$9.07K ﹤0.01% 3973
2017
Q4
$66K Sell
55,374
-5,036
-8% -$6.88K ﹤0.01% 4039
2017
Q3
$76K Sell
60,410
-24
-0% -$31 ﹤0.01% 4008
2017
Q2
$80K Sell
60,434
-240,583
-80% -$348K ﹤0.01% 4016
2017
Q1
$559K Buy
301,017
+1,740
+0.6% +$7.87K ﹤0.01% 3502
2016
Q4
$1.55M Buy
299,277
+22,358
+8% +$118K ﹤0.01% 3215
2016
Q3
$1.54M Buy
276,919
+457
+0.2% +$2.61K ﹤0.01% 3186
2016
Q2
$1.53M Buy
276,462
+28,155
+11% +$148K ﹤0.01% 3170
2016
Q1
$1.09M Buy
248,307
+16,696
+7% +$68.7K ﹤0.01% 3226
2015
Q4
$1.39M Buy
231,611
+51,725
+29% +$351K ﹤0.01% 3208
2015
Q3
$1.41M Buy
179,886
+126,957
+240% +$984K ﹤0.01% 3213
2015
Q2
$324K Buy
52,929
+23,452
+80% +$182K ﹤0.01% 3672
2015
Q1
$238K Buy
29,477
+1,861
+7% +$14K ﹤0.01% 3810
2014
Q4
$140K Hold
27,616
﹤0.01% 3901
2014
Q3
$143K Sell
27,616
-87
-0.3% -$561 ﹤0.01% 3934
2014
Q2
$215K Buy
27,703
+56
+0.2% +$396 ﹤0.01% 3840
2014
Q1
$193K Buy
27,647
+2,708
+11% +$21.1K ﹤0.01% 3798
2013
Q4
$149K Buy
24,939
+8,812
+55% +$57.6K ﹤0.01% 3788
2013
Q3
$126K Buy
16,127
+590
+4% +$2.74K ﹤0.01% 3774
2013
Q2
$59K Buy
+15,537
New +$63.7K ﹤0.01% 3905

Northern Trust's GNMX Position: Q1 2020 in Review

Northern Trust sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 50,541 shares — an estimated $7K sold.

Northern Trust first reported a position in GNMX in Q2 2013 and held it in 27 quarters. The position peaked at $1.55M in Q4 2016. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.

  • Northern Trust reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
  • Northern Trust sold 50,541 Aevi Genomic Medicine Inc shares in Q1 2020, an estimated $7K.
  • Northern Trust first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 27 quarters.
  • Northern Trust's Aevi Genomic Medicine Inc position peaked at $1.55M in Q4 2016.
  • 2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.

Based on Northern Trust's 13F filing for Q1 2020, filed 14 May 2020.